UroGen Pharma (NASDAQ:URGN) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.29) by 3.45 percent. This is a 73.33 percent increase over losses of $(1.05) per share from the same period last year. The company reported quarterly sales of $72.456 million which beat the analyst consensus estimate of $63.526 million by 14.06 percent. This is a 199.22 percent increase over sales of $24.215 million the same period last year.